PubRank

James K Liao

Author PubWeight™ 169.34‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation 2008 3.48
2 Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arterioscler Thromb Vasc Biol 2004 3.18
3 Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med 2002 3.17
4 Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 2008 2.68
5 Physiological role of ROCKs in the cardiovascular system. Am J Physiol Cell Physiol 2006 2.61
6 Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenase-derived eicosanoids. Circ Res 2002 2.53
7 Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 2003 2.39
8 Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 2002 2.39
9 Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003 2.30
10 Essential role of endothelial Notch1 in angiogenesis. Circulation 2005 2.28
11 Rho GTPases, statins, and nitric oxide. Circ Res 2005 2.21
12 Pleiotropic effects of statins. - Basic research and clinical perspectives -. Circ J 2010 2.13
13 Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke 2005 2.13
14 Decreased perivascular fibrosis but not cardiac hypertrophy in ROCK1+/- haploinsufficient mice. Circulation 2005 2.09
15 Ventricular septal defect and cardiomyopathy in mice lacking the transcription factor CHF1/Hey2. Proc Natl Acad Sci U S A 2002 2.04
16 Regulation of endothelial nitric oxide synthase and postnatal angiogenesis by Rac1. Circ Res 2008 2.04
17 Requirement of Rac1 in the development of cardiac hypertrophy. Proc Natl Acad Sci U S A 2006 2.02
18 ROCK1 mediates leukocyte recruitment and neointima formation following vascular injury. J Clin Invest 2008 1.92
19 Critical role of endothelial Notch1 signaling in postnatal angiogenesis. Circ Res 2006 1.91
20 Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. Arch Biochem Biophys 2005 1.91
21 Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease. Circ Res 2006 1.84
22 Rapid nongenomic actions of thyroid hormone. Proc Natl Acad Sci U S A 2006 1.79
23 NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy. J Mol Cell Cardiol 2003 1.75
24 Activation of the phosphatidylinositol 3-kinase/protein kinase Akt pathway mediates nitric oxide-induced endothelial cell migration and angiogenesis. Mol Cell Biol 2003 1.75
25 Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation 2004 1.73
26 RhoA/ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis. FASEB J 2010 1.67
27 Long-term statin use and psychological well-being. J Am Coll Cardiol 2003 1.66
28 FHL2/SLIM3 decreases cardiomyocyte survival by inhibitory interaction with sphingosine kinase-1. Circ Res 2006 1.63
29 Fingolimod provides long-term protection in rodent models of cerebral ischemia. Ann Neurol 2010 1.62
30 Targeting eNOS for stroke protection. Trends Neurosci 2004 1.60
31 Preservation of NO production by statins in the treatment of heart failure. Cardiovasc Res 2003 1.59
32 Smooth muscle Notch1 mediates neointimal formation after vascular injury. Circulation 2009 1.58
33 Increased Rho kinase activity in a Taiwanese population with metabolic syndrome. J Am Coll Cardiol 2007 1.46
34 Rho-kinase mediates hyperglycemia-induced plasminogen activator inhibitor-1 expression in vascular endothelial cells. Circulation 2005 1.45
35 Noninvasive method for assessing the human circadian clock using hair follicle cells. Proc Natl Acad Sci U S A 2010 1.43
36 Obesity increases vascular senescence and susceptibility to ischemic injury through chronic activation of Akt and mTOR. Sci Signal 2009 1.43
37 Deficiency of ROCK1 in bone marrow-derived cells protects against atherosclerosis in LDLR-/- mice. FASEB J 2008 1.41
38 Cloning of CYP2J2 gene and identification of functional polymorphisms. Mol Pharmacol 2002 1.41
39 Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice. J Clin Invest 2010 1.40
40 Rapid nontranscriptional activation of endothelial nitric oxide synthase mediates increased cerebral blood flow and stroke protection by corticosteroids. J Clin Invest 2002 1.40
41 Inhibition of apoptosis-regulated signaling kinase-1 and prevention of congestive heart failure by estrogen. Circulation 2007 1.39
42 11,12-epoxyeicosatrienoic acid (11,12-EET): structural determinants for inhibition of TNF-alpha-induced VCAM-1 expression. Bioorg Med Chem Lett 2003 1.38
43 Increased vascular senescence and impaired endothelial progenitor cell function mediated by mutation of circadian gene Per2. Circulation 2008 1.36
44 NF-κB and innate immunity in ischemic stroke. Ann N Y Acad Sci 2010 1.34
45 Roles of rho-associated kinase and oxidative stress in the pathogenesis of aortic stiffness. J Am Coll Cardiol 2007 1.33
46 Rho-kinase inhibition acutely augments blood flow in focal cerebral ischemia via endothelial mechanisms. J Cereb Blood Flow Metab 2006 1.32
47 Decreased vascular lesion formation in mice with inducible endothelial-specific expression of protein kinase Akt. J Clin Invest 2006 1.31
48 Linking Notch signaling to ischemic stroke. Proc Natl Acad Sci U S A 2008 1.28
49 A method for measuring Rho kinase activity in tissues and cells. Methods Enzymol 2008 1.27
50 A mouse model of diet-induced obesity and insulin resistance. Methods Mol Biol 2012 1.27
51 ROCKs as therapeutic targets in cardiovascular diseases. Expert Rev Cardiovasc Ther 2005 1.25
52 Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases. Drug Discov Today 2010 1.24
53 Tumor necrosis factor-alpha downregulates endothelial nitric oxide synthase mRNA stability via translation elongation factor 1-alpha 1. Circ Res 2008 1.24
54 1alpha,25-dihydroxyvitamin D3 induces vascular smooth muscle cell migration via activation of phosphatidylinositol 3-kinase. Circ Res 2002 1.20
55 Acute reduction of myocardial infarct size by a hydroxymethyl glutaryl coenzyme A reductase inhibitor is mediated by endothelial nitric oxide synthase. J Cardiovasc Pharmacol 2003 1.19
56 Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis 2008 1.19
57 Inhibition of MHC II gene transcription by nitric oxide and antioxidants. Curr Pharm Des 2004 1.19
58 Protective effects of statins involving both eNOS and tPA in focal cerebral ischemia. J Cereb Blood Flow Metab 2005 1.18
59 Rho-associated coiled-coil-forming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease. Trends Pharmacol Sci 2011 1.17
60 Molecular basis of cell membrane estrogen receptor interaction with phosphatidylinositol 3-kinase in endothelial cells. Arterioscler Thromb Vasc Biol 2003 1.14
61 Isoprenoid metabolism and the pleiotropic effects of statins. Curr Atheroscler Rep 2003 1.11
62 Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene. Circulation 2002 1.11
63 Distribution of sphingosine kinase activity and mRNA in rodent brain. J Neurochem 2007 1.11
64 Transcription factor CHF1/Hey2 suppresses cardiac hypertrophy through an inhibitory interaction with GATA4. Am J Physiol Heart Circ Physiol 2006 1.10
65 Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr Pharm Des 2009 1.09
66 Translational therapeutics of dipyridamole. Arterioscler Thromb Vasc Biol 2008 1.09
67 Nonnuclear actions of estrogen. Arterioscler Thromb Vasc Biol 2002 1.08
68 Folliculin, the product of the Birt-Hogg-Dube tumor suppressor gene, interacts with the adherens junction protein p0071 to regulate cell-cell adhesion. PLoS One 2012 1.08
69 Notch1 in bone marrow-derived cells mediates cardiac repair after myocardial infarction. Circulation 2011 1.06
70 Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein. Circ Res 2004 1.05
71 Rho kinase: an important mediator of atherosclerosis and vascular disease. Curr Pharm Des 2009 1.04
72 Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts. J Vasc Surg 2004 1.03
73 Functional interaction of endothelial nitric oxide synthase with a voltage-dependent anion channel. Proc Natl Acad Sci U S A 2002 1.03
74 Phosphatidylinositol 3-kinase/protein kinase Akt negatively regulates plasminogen activator inhibitor type 1 expression in vascular endothelial cells. Am J Physiol Heart Circ Physiol 2006 1.02
75 Notch signaling regulates endothelial progenitor cell activity during recovery from arterial injury in hypercholesterolemic mice. Circulation 2010 1.02
76 Induction of angiogenesis by heat shock protein 90 mediated by protein kinase Akt and endothelial nitric oxide synthase. Arterioscler Thromb Vasc Biol 2004 1.01
77 Additive effects of statin and dipyridamole on cerebral blood flow and stroke protection. J Cereb Blood Flow Metab 2008 1.00
78 Rho-associated kinase activity, endothelial function, and cardiovascular risk factors. Arterioscler Thromb Vasc Biol 2011 1.00
79 Identification of ROCK1 as an upstream activator of the JIP-3 to JNK signaling axis in response to UVB damage. Sci Signal 2008 0.99
80 Measurement of Rho-associated kinase (ROCK) activity in humans: validity of leukocyte p-MBS/t-MBS in comparison with vascular response to fasudil. Atherosclerosis 2010 0.99
81 Novel non-transcriptional mechanisms for estrogen receptor signaling in the cardiovascular system. Interaction of estrogen receptor alpha with phosphatidylinositol 3-OH kinase. Steroids 2002 0.98
82 Absence of TRAM restricts Toll-like receptor 4 signaling in vascular endothelial cells to the MyD88 pathway. Circ Res 2006 0.98
83 gamma-Secretase inhibitor reduces diet-induced atherosclerosis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun 2009 0.98
84 A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterol-independent mechanisms. Ann Med 2003 0.97
85 Rho/Rho-associated coiled-coil forming kinase pathway as therapeutic targets for statins in atherosclerosis. Antioxid Redox Signal 2013 0.96
86 Berberine suppresses MEK/ERK-dependent Egr-1 signaling pathway and inhibits vascular smooth muscle cell regrowth after in vitro mechanical injury. Biochem Pharmacol 2006 0.96
87 FHL2 prevents cardiac hypertrophy in mice with cardiac-specific deletion of ROCK2. FASEB J 2012 0.95
88 Novel aspects of the roles of Rac1 GTPase in the cardiovascular system. Curr Opin Pharmacol 2010 0.95
89 Drug Insight: statins and stroke. Nat Clin Pract Cardiovasc Med 2005 0.94
90 Rho-associated coiled-coil-containing kinase 2 deficiency in bone marrow-derived cells leads to increased cholesterol efflux and decreased atherosclerosis. Circulation 2012 0.93
91 Nontranscriptional actions of the glucocorticoid receptor. J Mol Med (Berl) 2003 0.92
92 Increased leukocyte rho kinase (ROCK) activity and endothelial dysfunction in cigarette smokers. Hypertens Res 2010 0.92
93 Calcium channel blocker and Rho-associated kinase activity in patients with hypertension. J Hypertens 2011 0.91
94 Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event. Am J Cardiol 2008 0.90
95 Increased leukocyte ROCK activity in patients after acute ischemic stroke. Brain Res 2008 0.90
96 Vascular protection by estrogen in ischemia-reperfusion injury requires endothelial nitric oxide synthase. Am J Physiol Heart Circ Physiol 2002 0.89
97 Striatal neurons expressing full-length mutant huntingtin exhibit decreased N-cadherin and altered neuritogenesis. Hum Mol Genet 2011 0.89
98 Notch signaling as an important mediator of cardiac repair and regeneration after myocardial infarction. Trends Cardiovasc Med 2010 0.88
99 Rapid effects of statins: from prophylaxis to therapy for ischemic stroke. Arterioscler Thromb Vasc Biol 2003 0.88
100 Pitavastatin-induced angiogenesis and arteriogenesis is mediated by Notch1 in a murine hindlimb ischemia model without induction of VEGF. Lab Invest 2011 0.87
101 Rho-associated kinase activity is a predictor of cardiovascular outcomes. Hypertension 2013 0.86
102 Increased leukocyte Rho-associated coiled-coil containing protein kinase activity predicts the presence and severity of coronary vasospastic angina. Atherosclerosis 2012 0.85
103 Elevated rho-kinase activity as a marker indicating atherosclerosis and inflammation burden in polyvascular disease patients with concomitant coronary and peripheral arterial disease. Clin Cardiol 2013 0.84
104 Targeting eNOS and beyond: emerging heterogeneity of the role of endothelial Rho proteins in stroke protection. Expert Rev Neurother 2009 0.84
105 Activated Rho kinase mediates diabetes-induced elevation of vascular arginase activation and contributes to impaired corpora cavernosa relaxation: possible involvement of p38 MAPK activation. J Sex Med 2013 0.84
106 ROCKs as immunomodulators of stroke. Expert Opin Ther Targets 2012 0.84
107 Statins exert the pleiotropic effects through small GTP-binding protein dissociation stimulator upregulation with a resultant Rac1 degradation. Arterioscler Thromb Vasc Biol 2013 0.83
108 Simvastatin preserves cardiac function in genetically determined cardiomyopathy. J Cardiovasc Pharmacol 2004 0.83
109 Inhibition of Rho-kinase attenuates endothelial-leukocyte interaction during ischemia-reperfusion injury. Vasc Med 2012 0.83
110 Rac1 is a critical mediator of endothelium-derived neurotrophic activity. Sci Signal 2009 0.83
111 Rho-kinase: a potential link between hypercholesterolemia and abnormal vascular smooth muscle contraction. Circ Res 2006 0.82
112 Increased Rho kinase activity in congestive heart failure. Eur J Heart Fail 2012 0.81
113 Inhibition of major histocompatibility complex class II gene transcription by nitric oxide and antioxidants. J Biol Chem 2002 0.81
114 Potential serum biomarkers in the pathophysiological processes of stroke. Expert Rev Neurother 2014 0.81
115 Mitohormesis: another pleiotropic effect of statins? Eur Heart J 2011 0.80
116 Non-nuclear actions of estrogen: new targets for prevention and treatment of cardiovascular disease. Mol Interv 2002 0.79
117 Abrogation of airway hyperresponsiveness but not inflammation by rho kinase insufficiency. Clin Exp Allergy 2015 0.79
118 Shedding growth factors in cardiac hypertrophy. Nat Med 2002 0.79
119 Statins and the myocardium. Semin Vasc Med 2004 0.79
120 Dynamic regulation of endothelial NOS mediated by competitive interaction with alpha-actinin-4 and calmodulin. FASEB J 2008 0.78
121 Statin therapy: having the good without the bad. Hypertension 2004 0.78
122 Simvastatin reverses cardiac hypertrophy caused by disruption of the bradykinin 2 receptor. Can J Physiol Pharmacol 2008 0.78
123 A combination of increased Rho kinase activity and N-terminal pro-B-type natriuretic peptide predicts worse cardiovascular outcome in patients with acute coronary syndrome. Int J Cardiol 2012 0.78
124 ROCK inhibition prevents fetal serum-induced alteration in structure and function of organ-cultured mesenteric artery. J Muscle Res Cell Motil 2011 0.77
125 Elevated homocysteine and C-reactive protein levels independently predict worsening prognosis after stroke in Chinese patients. J Huazhong Univ Sci Technolog Med Sci 2010 0.77
126 Rho Kinases and Cardiac Remodeling. Circ J 2016 0.76
127 Rac1 and connective tissue growth factor. The missing link between atrial remodeling and the pathogenesis of atrial fibrillation? J Am Coll Cardiol 2010 0.76
128 Squalene synthase inhibitor lapaquistat acetate: could anything be better than statins? Circulation 2011 0.76
129 Primary prevention of cardiovascular disease with pravastatin. Curr Atheroscler Rep 2007 0.75
130 Long-term follow-up of the West of Scotland Coronary Prevention Study. Curr Atheroscler Rep 2008 0.75
131 HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. Curr Atheroscler Rep 2008 0.75
132 Effect of torcetrapib in patients at high risk for coronary events. Curr Atheroscler Rep 2008 0.75
133 Effect of rosiglitazone on the frequency of diabetes. Curr Atheroscler Rep 2007 0.75
134 Role of angiotensin II receptor subtypes in porcine basilar artery: functional, radioligand binding, and cell culture studies. Life Sci 2005 0.75
135 Statins and myocardial hypertrophy. Coron Artery Dis 2004 0.75
136 Effect of ramipril on the incidence of diabetes. Curr Atheroscler Rep 2007 0.75
137 Fibroblast deletion of ROCK2 attenuates cardiac hypertrophy, fibrosis, and diastolic dysfunction. JCI Insight 2017 0.75